Aliases & Classifications for Mumps

MalaCards integrated aliases for Mumps:

Name: Mumps 12 72 49 51 40 3 41 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:10264
ICD10 32 B26 B26.9 B26.8
ICD9CM 34 072
MeSH 41 D009107
NCIt 46 C29888
UMLS 69 C0026780

Summaries for Mumps

MedlinePlus : 40 Mumps is an illness caused by the mumps virus. It starts with Fever Headache Muscle aches Tiredness Loss of appetite After that, the salivary glands under the ears or jaw become swollen and tender. The swelling can be on one or both sides of the face. Symptoms last 7 to 10 days. Serious complications are rare. You can catch mumps by being with another person who has it. There is no treatment for mumps, but the measles-mumps-rubella (MMR) vaccine can prevent it. Before the routine vaccination program in the United States, mumps was a common illness in infants, children and young adults. Now it is a rare disease in the U.S. Centers for Disease Control and Prevention

MalaCards based summary : Mumps is related to primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection and rubella, and has symptoms including fever, headache and muscle aches. An important gene associated with Mumps is STAT2 (Signal Transducer And Activator Of Transcription 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Vaccines and Antibodies have been mentioned in the context of this disorder. Affiliated tissues include salivary gl, salivary gland and testes, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A viral infectious disease that results_in inflammation located in salivary gland, has material basis in Mumps virus, which is transmitted_by droplet spread of saliva or mucus from the mouth, nose, or throat of an infected person, or transmitted_by contaminated fomites. The infection has symptom fever, has symptom headache, has symptom muscle aches, has symptom tiredness, has symptom loss of appetite, has symptom swollen and tender salivary glands under the ears or jaw on one or both sides of the face.

CDC : 3 Mumps is a contagious disease caused by a virus. It typically starts with a few days of fever, headache, muscle aches, tiredness, and loss of appetite, followed by swollen salivary glands. You can protect yourself and your family against mumps with vaccination.

Wikipedia : 72 Mumps is a viral disease caused by the mumps virus. Initial signs and symptoms often include fever,... more...

Related Diseases for Mumps

Diseases in the Mumps family:

Congenital Mumps

Diseases related to Mumps via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 261)
# Related Disease Score Top Affiliating Genes
1 primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection 33.7 IFNAR2 STAT2
2 rubella 31.9 CD40LG HLA-DRB1 IFNAR2 IL10RB
3 measles 30.6 CD40LG CD46 IFNAR2 IFNG IL2 STAT1
4 recurrent respiratory papillomatosis 29.5 HLA-DRB1 IL2
5 panencephalitis, subacute sclerosing 29.4 CD40LG CD46
6 tetanus 29.0 CD40LG IFNG IL2 IL2RA
7 exanthem 29.0 CD40LG IL2 TNFRSF1A
8 rheumatic disease 28.8 CD40LG HLA-DRB1 IFNG IL2RA
9 posterior uveitis 28.7 IFNG IL2 IL2RA
10 combined immunodeficiency, x-linked 28.6 CD40LG IL2 IL2RA
11 bone inflammation disease 28.5 CD40LG HLA-DRB1 IFNG IL2
12 multiple sclerosis 27.8 HLA-DRB1 IFNG IL2 IL2RA STAT1 TNFRSF1A
13 congenital mumps 12.0
14 acute disseminated encephalomyelitis 11.3
15 endotheliitis 11.2
16 testicular microlithiasis 10.8
17 infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovascular malformations 10.8
18 immunodeficiency 45 10.8
19 male infertility 10.8
20 salivary gland disease 10.8
21 immune-mediated encephalomyelitis 10.8
22 postinfectious encephalomyelitis 10.8
23 zika fever 10.4 CD40LG STAT1
24 axillary adenitis 10.4 CD40LG STAT1
25 orchitis 10.4
26 meningitis 10.3
27 chronic beryllium disease 10.3 HLA-DRB1 IFNG
28 campylobacteriosis 10.3 IFNG STAT1
29 coccidioidomycosis 10.3 CD40LG STAT1
30 aseptic meningitis 10.3
31 parotitis 10.2
32 rheumatoid factor-negative juvenile idiopathic arthritis 10.2 HLA-DRB1 IL2RA
33 aging 10.2
34 histoplasmosis 10.2 HLA-DRB1 IFNG STAT1
35 eosinophilia-myalgia syndrome 10.2 HLA-DRB1 IFNG
36 african tick-bite fever 10.2 CD40LG IFNG
37 rabies 10.2 CD40LG STAT1 STAT2
38 cat-scratch disease 10.2 CD40LG IFNG
39 hyperlucent lung 10.2 IFNG IL2RA
40 sporotrichosis 10.2 CD40LG IFNG
41 retinitis pigmentosa 75 10.2 IL10RB TNFRSF1A
42 opportunistic mycosis 10.1 CD40LG IFNG STAT1
43 severe acute respiratory syndrome 10.1 CD40LG IFNG STAT1
44 hepatitis 10.1
45 meningoencephalitis 10.1
46 influenza 10.1
47 encephalitis 10.1
48 central nervous system vasculitis 10.1 CD40LG HLA-DRB1 IFNG
49 hemorrhagic fever 10.1 CD40LG HLA-DRB1 IFNG
50 chronic graft versus host disease 10.1 IFNG IL2RA

Graphical network of the top 20 diseases related to Mumps:



Diseases related to Mumps

Symptoms & Phenotypes for Mumps

Symptoms:

12
  • fever
  • headache
  • muscle aches
  • tiredness
  • loss of appetite
  • swollen

UMLS symptoms related to Mumps:


pruritus, fever

GenomeRNAi Phenotypes related to Mumps according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.7 CD40LG IL2 IL2RA RIPK1 STAT1 TNFRSF1A
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.7 CD40LG IL2 IL2RA RIPK1 STAT1 TNFRSF1A

MGI Mouse Phenotypes related to Mumps:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.18 STAT1 STAT2 TNFRSF1A RIPK1 IRF2 IL12RB2
2 immune system MP:0005387 10.07 RIPK1 STAT1 STAT2 TNFRSF1A IRF2 IL12RB2
3 cardiovascular system MP:0005385 10.06 STAT1 TNFRSF1A IRAK1 CD40LG IL12RB2 CD46
4 endocrine/exocrine gland MP:0005379 10.06 RIPK1 STAT1 TNFRSF1A IL12RB2 CD40LG IL2
5 digestive/alimentary MP:0005381 10.03 RIPK1 STAT1 TNFRSF1A IL12RB2 IL2 IFNG
6 homeostasis/metabolism MP:0005376 10.02 RIPK1 STAT1 TNFRSF1A IL10RB CD40LG IL12RB2
7 mortality/aging MP:0010768 9.73 RIPK1 STAT1 STAT2 TNFRSF1A IRF2 CD40LG
8 liver/biliary system MP:0005370 9.7 RIPK1 STAT1 TNFRSF1A IL10RB IL12RB2 IL2
9 neoplasm MP:0002006 9.1 STAT1 TNFRSF1A IL12RB2 IFNAR2 IL2 IFNG

Drugs & Therapeutics for Mumps

Drugs for Mumps (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 64)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
2 Antibodies Phase 4,Phase 2,Phase 1
3 Immunoglobulins Phase 4,Phase 2,Phase 1
4 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2
5 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2
6 Liver Extracts Phase 4
7
Aluminum hydroxide Approved, Investigational Phase 3,Phase 2 21645-51-2
8
Tetracycline Approved, Vet_approved Phase 3,Phase 2 60-54-8 5353990
9
Lactitol Investigational Phase 3,Phase 2 585-86-4 3871
10 PENTA Phase 3,Phase 2
11 Anti-Bacterial Agents Phase 3,Phase 2
12 Anti-Infective Agents Phase 3,Phase 2
13
Altretamine Approved Phase 2 645-05-6 2123
14
Daclizumab Approved, Investigational Phase 2 152923-56-3
15
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
16
Mycophenolate mofetil Approved, Investigational Phase 2 128794-94-5 5281078
17
Mycophenolic acid Approved Phase 2 24280-93-1 446541
18
Obinutuzumab Approved, Investigational Phase 2,Phase 1 949142-50-1
19
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
20
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
21 Anticoagulants Phase 2
22 Fibrinolytic Agents Phase 2
23 Antibodies, Monoclonal Phase 2
24 Immunosuppressive Agents Phase 2
25 Interleukin-2 Phase 2
26 Peripheral Nervous System Agents Phase 2
27 Antibiotics, Antitubercular Phase 2
28 Antiemetics Phase 2
29 Anti-Inflammatory Agents Phase 2
30 Antineoplastic Agents, Hormonal Phase 2
31 Antitubercular Agents Phase 2
32 Autonomic Agents Phase 2
33 Gastrointestinal Agents Phase 2
34 glucocorticoids Phase 2
35 Hormone Antagonists Phase 2
36 Hormones Phase 2
37 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
38 Methylprednisolone acetate Phase 2
39 Methylprednisolone Hemisuccinate Phase 2
40 Neuroprotective Agents Phase 2
41 Prednisolone acetate Phase 2
42 Prednisolone hemisuccinate Phase 2
43 Prednisolone phosphate Phase 2
44 Protective Agents Phase 2
45 gamma-Globulins Phase 1
46 Immunoglobulins, Intravenous Phase 1
47 Rho(D) Immune Globulin Phase 1
48
Acetylcholine Approved 51-84-3 187
49
Adalimumab Approved 331731-18-1 16219006
50
Azathioprine Approved 446-86-6 2265

Interventional clinical trials:

(show top 50) (show all 137)

# Name Status NCT ID Phase Drugs
1 The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine Unknown status NCT02153866 Phase 4
2 Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations Completed NCT01777529 Phase 4
3 Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine Completed NCT02880865 Phase 4
4 Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis Completed NCT00731965 Phase 4
5 Measles, Mumps, and Rubella (MMR) Immunity in College Students Completed NCT00962819 Phase 4
6 Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00126997 Phase 4
7 Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine Completed NCT00313950 Phase 4
8 Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine Completed NCT03160820 Phase 4
9 MMR Vaccination Among HIV-infected Adults Completed NCT02724852 Phase 4
10 Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) Completed NCT00326183 Phase 4
11 Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067) Completed NCT00312858 Phase 4
12 Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. Completed NCT00388440 Phase 4
13 MMR and Varicella Vaccine in Premature Infants Completed NCT00156559 Phase 4
14 Safety & Immunogenicity of MMR Vaccine by DSJI to That by Needle-Syringe in 15-18 Months Old Children Completed NCT02253407 Phase 4
15 Safety Study of a Refrigerator-stable Formulation of VARIVAX® Completed NCT00432731 Phase 4
16 Study of the Influence of Vaccination in HIV Viral Load and Immunologic Responses Against HIV Completed NCT00329251 Phase 4
17 Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts Recruiting NCT03183765 Phase 4 Measles-Mumps-Rubella Vaccine
18 Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines Recruiting NCT03368495 Phase 4
19 Homeopathic Vaccine Trial Recruiting NCT02825368 Phase 4
20 Induction of Immunity Against Measles in Pediatric Liver Transplant Recipients Recruiting NCT01770119 Phase 4
21 Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR Active, not recruiting NCT02325310 Phase 4
22 Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination Not yet recruiting NCT03350698 Phase 4
23 Responses of Premature Infants to Measles-Mumps-Rubella (MMR) and Varicella Vaccines Terminated NCT00138255 Phase 4
24 Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants Unknown status NCT01763268 Phase 2, Phase 3
25 Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants Completed NCT02692599 Phase 3
26 Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older Completed NCT02058563 Phase 3
27 A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED) Completed NCT00092391 Phase 3
28 Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00127023 Phase 3
29 Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00127010 Phase 3
30 Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers Completed NCT01188343 Phase 3
31 Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027) Completed NCT01536405 Phase 3
32 Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months. Completed NCT01991899 Phase 3
33 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life Completed NCT01681992 Phase 3
34 Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age Completed NCT02184572 Phase 3
35 Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016) Completed NCT00092430 Phase 3
36 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age Completed NCT01621802 Phase 3
37 Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 Completed NCT00751348 Phase 3
38 Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy Children Completed NCT00192491 Phase 3
39 Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children Completed NCT00197015 Phase 3
40 Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox Completed NCT00226499 Phase 3
41 Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children Completed NCT01506193 Phase 3
42 ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED) Completed NCT00975507 Phase 3
43 Safety Study of ProQuad® rHA in Infants (V221-037) Completed NCT00560755 Phase 3
44 Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM Completed NCT00969436 Phase 3
45 Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly Completed NCT00432042 Phase 3
46 Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine Completed NCT00406211 Phase 3
47 Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix®) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M M R®II), in Children 12 to 15 Months of Age Completed NCT01702428 Phase 3
48 Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED) Completed NCT00985153 Phase 3
49 A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014) Completed NCT00985166 Phase 3
50 Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers Completed NCT00422292 Phase 3

Search NIH Clinical Center for Mumps

Cochrane evidence based reviews: mumps

Genetic Tests for Mumps

Anatomical Context for Mumps

The Foundational Model of Anatomy Ontology organs/tissues related to Mumps:

18
Salivary Gl

MalaCards organs/tissues related to Mumps:

38
Salivary Gland, Testes, Liver, B Cells, Skin, Heart, T Cells

Publications for Mumps

Articles related to Mumps:

(show top 50) (show all 839)
# Title Authors Year
1
Granulomatosis With Polyangiitis Associated With Mumps Viral Infection. ( 29424761 )
2018
2
Assessment of Humoral Immunity to Hepatitis B, Measles, Rubella, and Mumps in Children After Chemotherapy. ( 29309372 )
2018
3
Measles, mumps, and rubella antibody patterns of persistence and rate of decline following the second dose of the MMR vaccine. ( 29317117 )
2018
4
Assessment of mumps-containing vaccine effectiveness during an outbreak: Importance to introduce the 2-dose schedule for China. ( 29377772 )
2018
5
Polymorphisms in the Wilms Tumor Gene Are Associated With Interindividual Variations in Rubella Virus-Specific Cellular Immunity After Measles-Mumps-Rubella II Vaccination. ( 29253144 )
2018
6
Mumps infection but not childhood vaccination induces persistent polyfunctional CD8<sup>+</sup>T-cell memory. ( 29339261 )
2018
7
Recommendation of the Advisory Committee on Immunization Practices for Use of a Third Dose of Mumps Virus-Containing Vaccine in Persons at Increased Risk for Mumps During an Outbreak. ( 29324728 )
2018
8
Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in India: A randomized, parallel group, non-inferiority trial. ( 29395526 )
2018
9
Utility of neutralization test for the laboratory diagnosis of suspected mumps cases. ( 29363797 )
2018
10
Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation. ( 29426830 )
2018
11
A Complication after Percutaneous Nephrolithotomy: Anesthesia Mumps. ( 28928593 )
2017
12
Tackling mumps in a public health setting: loopholes in disease surveillance. ( 28843408 )
2017
13
Shift within age-groups of mumps incidence, hospitalizations and severe complications in a highly vaccinated population. Spain, 1998-2014. ( 28687402 )
2017
14
Magnetic Resonance Imaging Findings of Mumps Meningoencephalitis with Bilateral Hippocampal Lesions without Preceding Acute Parotitis: A Case Report. ( 28246518 )
2017
15
Mumps Virus SH Protein Inhibits NF-I_B Activation by Interacting with Tumor Necrosis Factor Receptor 1, Interleukin-1 Receptor 1, and Toll-Like Receptor 3 Complexes. ( 28659487 )
2017
16
Three Complete Genome Sequences of Genotype G Mumps Virus from the 2016 Outbreak in Arkansas, USA. ( 28798162 )
2017
17
Anti-mumps IgM antibody positive rate with sudden sensorineural hearing loss using second-generation enzyme immunoassay: A retrospective, multi-institutional investigation in Hokkaido, Japan. ( 29224848 )
2017
18
Mumps Epidemiology and Mumps Virus Genotypes Circulating in Mainland China during 2013-2015. ( 28085897 )
2017
19
Reemergence of mumps in SALo Paulo, Brazil - the urgent need for booster shot campaign to prevent a serious infectious disease. ( 28954076 )
2017
20
Comparison of cidofovir and the measles, mumps, and rubella vaccine in the treatment of recurrent respiratory papillomatosis. ( 28231366 )
2017
21
Heat shock protein 90 ensures efficient mumps virus replication by assisting with viral polymerase complex formation. ( 28053100 )
2017
22
Enhancing global vaccine pharmacovigilance: Proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination. ( 28558983 )
2017
23
Pain caused by measles, mumps, and rubella vaccines: A systematic literature review. ( 28893478 )
2017
24
The potential dysfunction of otolith organs in patients after mumps infection. ( 28746415 )
2017
25
Campaign Mode MMR Vaccination to Control Outbreak of Mumps in a Highly Vaccinated Population: Evidence-based Medicine viewpoint. ( 29317561 )
2017
26
A questionnaire survey for parents in Nara prefecture, Japan about mumps vaccination. ( 29288550 )
2017
27
Non-specific effects of measles, mumps, and rubella (MMR) vaccination in high income setting: population based cohort study in the Netherlands. ( 28855159 )
2017
28
Campaign Mode MMR Vaccination to Control Outbreak of Mumps in a Highly Vaccinated Population: Pediatrician's Viewpoint. ( 29317562 )
2017
29
The pathogenesis of iodide mumps: A case report. ( 29382013 )
2017
30
Mumps Virus Nucleoprotein and Hemagglutinin-Specific Antibody Response Following a Third Dose of Measles Mumps Rubella Vaccine. ( 29308410 )
2017
31
Severe Complications of Mumps. ( 28891485 )
2017
32
Pseudotumoral acute cerebellitis associated with mumps infection in a child. ( 28868306 )
2017
33
A case of mumps-related acute encephalopathy with biphasic seizures and late reduced diffusion. ( 28501474 )
2017
34
Static model simulation for routine mumps vaccination in Japan: with a result of mumps-related complications in a Japanese community hospital. ( 28775976 )
2017
35
Mumps makes a comeback: What nurses need to know. ( 28027128 )
2017
36
An outbreak of mumps with genetic strain variation in a highly vaccinated student population in Scotland. ( 28903791 )
2017
37
Complete Genome Sequence of Mumps Virus Isolated from Karnataka State, India. ( 28082488 )
2017
38
Mumps, Measles, and Rubella Vaccine for the Treatment of a Recalcitrant Subungual Wart. ( 28709617 )
2017
39
Mumps transmission in social networks: a cohort study. ( 28068914 )
2017
40
Evaluation of Combination Measles-Mumps-Rubella-Varicella Vaccine Introduction in Australia. ( 28806450 )
2017
41
Utilization and impact of European immunization week to increase measles, mumps, rubella vaccine uptake in Austria in 2016. ( 28797728 )
2017
42
Ongoing mumps outbreak in Israel, January to August 2017. ( 28877843 )
2017
43
Complete Genome Sequences of Mumps and Measles Virus Isolates from Three States in the United States. ( 28818890 )
2017
44
Third Dose of MMR Vaccine for Mumps Control. ( 29239596 )
2017
45
Voluntary termination of pregnancy: An opportunity for Measles, Mumps and Rubella vaccination in an Italian healthcare local unit. ( 29261361 )
2017
46
Pancreatic pseudocyst after measles, mumps, and rubella vaccination. ( 28082255 )
2017
47
Campaign Mode MMR Vaccination to Control Outbreak of Mumps in a Highly Vaccinated Population: Virologist's viewpoint. ( 29317563 )
2017
48
Modelling the Transmission Dynamics and Control of Mumps in Mainland China. ( 29278378 )
2017
49
A New CombinedA VaccineA Against Measles, Mumps, Rubella and Varicella in India. ( 29317560 )
2017
50
Forecasting the Incidence of Mumps in Zibo City Based on a SARIMA Model. ( 28817101 )
2017

Variations for Mumps

Expression for Mumps

Search GEO for disease gene expression data for Mumps.

Pathways for Mumps

Pathways related to Mumps according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 CD40LG CD46 HLA-DRB1 IFNAR2 IFNG IL10RB
2
Show member pathways
13.83 CD40LG IL10RB IL12RB2 IL2 IL2RA IRAK1
3
Show member pathways
13.64 CD40LG IFNAR2 IFNG IL10RB IL12RB2 IL2
4
Show member pathways
13.54 IFNAR2 IFNG IL10RB IL12RB2 IL2 IL2RA
5
Show member pathways
13.4 CD40LG IL10RB IL12RB2 IL2 IL2RA IRAK1
6
Show member pathways
13.27 CD40LG IL10RB IL12RB2 IL2 IL2RA TNFRSF1A
7
Show member pathways
13.24 HLA-DRB1 IFNG IL2 IL2RA IRAK1 STAT1
8
Show member pathways
12.99 IFNAR2 IL2 IL2RA STAT1 STAT2 TNFRSF1A
9
Show member pathways
12.94 IFNAR2 IRAK1 RIPK1 STAT1 STAT2
10
Show member pathways
12.89 CD40LG HLA-DRB1 IFNG IL2 IL2RA STAT1
11 12.89 IFNAR2 IFNG IL12RB2 IL2 IL2RA STAT1
12
Show member pathways
12.88 CD40LG HLA-DRB1 IFNAR2 IFNG IL10RB IL12RB2
13
Show member pathways
12.71 CD40LG IL2 IRAK1 RIPK1 TNFRSF1A
14
Show member pathways
12.69 CD40LG IFNG RIPK1 STAT1 TNFRSF1A
15
Show member pathways
12.65 CD46 HLA-DRB1 IFNAR2 IFNG IL2 IL2RA
16
Show member pathways
12.62 IFNG IL10RB IL2 RIPK1 STAT1
17
Show member pathways
12.62 HLA-DRB1 IFNG IL10RB IL12RB2 IL2 IL2RA
18
Show member pathways
12.61 CD40LG HLA-DRB1 IFNAR2 IFNG IL10RB IL12RB2
19
Show member pathways
12.6 HLA-DRB1 IFNAR2 IFNG IRF2 STAT1 STAT2
20
Show member pathways
12.54 IFNAR2 STAT1 STAT2 TNFRSF1A
21
Show member pathways
12.54 IFNAR2 IFNG IL2 IRAK1 RIPK1 STAT1
22 12.42 HLA-DRB1 IL2 IL2RA TNFRSF1A
23
Show member pathways
12.39 CD40LG HLA-DRB1 IL2 IL2RA
24 12.36 HLA-DRB1 IFNG IL10RB IRAK1 RIPK1
25
Show member pathways
12.31 IFNAR2 IFNG STAT1 STAT2
26
Show member pathways
12.3 IFNAR2 IFNG IL10RB IL12RB2 IL2 IL2RA
27 12.28 HLA-DRB1 IFNG IL10RB IRAK1 STAT1 TNFRSF1A
28
Show member pathways
12.27 CD40LG HLA-DRB1 IFNG IL10RB IRAK1 STAT1
29
Show member pathways
12.24 IFNAR2 IFNG RIPK1 STAT1 STAT2 TNFRSF1A
30
Show member pathways
12.18 IFNAR2 IFNG IL2 IRF2 STAT1 STAT2
31 12.13 IFNAR2 RIPK1 STAT1 STAT2 TNFRSF1A
32 12.12 IFNAR2 IFNG STAT1 STAT2 TNFRSF1A
33
Show member pathways
12.11 IFNG IL2 IL2RA STAT1
34
Show member pathways
12 IL2 IL2RA STAT1
35
Show member pathways
12 IFNG IL12RB2 IL2 STAT1 STAT2
36 11.97 IFNG IL2 IL2RA
37
Show member pathways
11.97 HLA-DRB1 IFNG IL12RB2 IL2 IL2RA IRAK1
38 11.95 CD40LG IRAK1 RIPK1 TNFRSF1A
39 11.88 CD40LG CD46 IFNG IL2 IL2RA IRAK1
40 11.87 IFNG IL12RB2 IL2 IL2RA
41
Show member pathways
11.84 CD40LG IFNG IL2 IL2RA
42
Show member pathways
11.82 CD40LG IRAK1 RIPK1 TNFRSF1A
43 11.81 IFNG IL2 STAT1
44 11.77 HLA-DRB1 STAT1 STAT2
45 11.76 IFNG IL2 IRF2
46
Show member pathways
11.74 CD40LG IFNG IL2 TNFRSF1A
47
Show member pathways
11.72 IFNAR2 IFNG IL2 IL2RA
48 11.7 IFNAR2 IFNG IL2
49 11.67 IFNAR2 IFNG IL10RB IL12RB2 IL2 IL2RA
50 11.62 IFNAR2 STAT1 STAT2

GO Terms for Mumps

Cellular components related to Mumps according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.55 CD40LG CD46 HLA-DRB1 IL2RA TNFRSF1A
2 plasma membrane GO:0005886 9.36 CD40LG CD46 HLA-DRB1 IFNAR2 IL10RB IL12RB2
3 external side of plasma membrane GO:0009897 9.26 CD40LG HLA-DRB1 IL12RB2 IL2RA

Biological processes related to Mumps according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.97 CD46 HLA-DRB1 IL2 IL2RA IRAK1
2 inflammatory response GO:0006954 9.93 CD40LG IL10RB IL2RA TNFRSF1A
3 cytokine-mediated signaling pathway GO:0019221 9.83 IL10RB IL12RB2 IRAK1 TNFRSF1A
4 cell surface receptor signaling pathway GO:0007166 9.83 IFNAR2 IFNG IL12RB2 IL2RA TNFRSF1A
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.81 CD40LG IRAK1 RIPK1
6 tumor necrosis factor-mediated signaling pathway GO:0033209 9.8 CD40LG RIPK1 STAT1 TNFRSF1A
7 immune response GO:0006955 9.8 CD40LG HLA-DRB1 IFNG IL10RB IL2 IL2RA
8 negative regulation of inflammatory response GO:0050728 9.77 IL2 IL2RA TNFRSF1A
9 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.73 IFNG IL2 TNFRSF1A
10 interleukin-12-mediated signaling pathway GO:0035722 9.71 IFNG IL12RB2 STAT1
11 viral process GO:0016032 9.7 CD46 HLA-DRB1 IRAK1 RIPK1 STAT1 STAT2
12 interferon-gamma-mediated signaling pathway GO:0060333 9.67 HLA-DRB1 IFNG IRF2 STAT1
13 JAK-STAT cascade GO:0007259 9.65 IFNAR2 STAT1 STAT2
14 regulation of type I interferon-mediated signaling pathway GO:0060338 9.63 IFNAR2 STAT1 STAT2
15 positive regulation of T cell differentiation GO:0045582 9.62 IL2 IL2RA
16 positive regulation of T cell proliferation GO:0042102 9.62 CD40LG CD46 IL2 IL2RA
17 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.61 IFNG STAT1
18 inflammatory response to antigenic stimulus GO:0002437 9.61 HLA-DRB1 IL2RA
19 positive regulation of regulatory T cell differentiation GO:0045591 9.59 CD46 IL2
20 response to interferon-beta GO:0035456 9.58 IFNAR2 STAT1
21 death-inducing signaling complex assembly GO:0071550 9.58 RIPK1 TNFRSF1A
22 regulation of regulatory T cell differentiation GO:0045589 9.58 IFNG IL2 IL2RA
23 negative regulation of lymphocyte proliferation GO:0050672 9.55 IL2 IL2RA
24 regulation of T cell homeostatic proliferation GO:0046013 9.51 IL2 IL2RA
25 defense response to virus GO:0051607 9.43 IFNAR2 IFNG IL10RB IRF2 STAT1 STAT2
26 type I interferon signaling pathway GO:0060337 9.02 IFNAR2 IRAK1 IRF2 STAT1 STAT2
27 apoptotic process GO:0006915 10.02 IFNG IL2RA RIPK1 STAT1 TNFRSF1A

Molecular functions related to Mumps according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ubiquitin-like protein ligase binding GO:0044389 8.62 STAT1 STAT2

Sources for Mumps

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....